Corbus和Arcus制药公司通过2025年11月3日结束的股票销售筹集了3.25亿美元。 Corbus and Arcus Pharmaceuticals raised $325 million combined through stock offerings set to close Nov. 3, 2025.

Corbus制药公司公开出价470万股,每股13.00美元,预先拨款100万股,12.99999美元,在开支前筹得约7 500万美元。 Corbus Pharmaceuticals priced a public offering of 4.7 million shares at $13.00 each and pre-funded warrants for 1.0 million shares at $12.9999, raising about $75 million before expenses. 该公司计划将收益用于临床发展、周转资金和一般公司目的。 The company plans to use proceeds for clinical development, working capital, and general corporate purposes. 30天的选项允许承保人购买多达865 384份额外股份。 A 30-day option allows underwriters to buy up to 865,384 additional shares. 预计将于2025年11月3日关闭的这项提议由Jeffery LLC和其他承保人管理。 The offering, expected to close on November 3, 2025, is managed by Jefferies LLC and other underwriters. Arcus生物科学公司还以每股18.25美元的1 370万股公开出价,在开销前筹集2.5亿美元,30天可选择再购买2.55亿股。 Arcus Biosciences also priced a public offering of 13.7 million shares at $18.25 each, raising $250 million before expenses, with a 30-day option for 2.055 million additional shares. 由Leerink Partners和其他人管理的这项提议预计也将于2025年11月3日结束。 The offering, managed by Leerink Partners and others, is also expected to close on November 3, 2025. 这两家公司都强调,前瞻性声明涉及风险和不确定性。 Both companies emphasize that forward-looking statements involve risks and uncertainties.